QuidelOrtho Expects Q1 2026 Revenue Decline Amid Weak Sales
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy QDEL?
Source: seekingalpha
- Revenue Guidance Downgrade: QuidelOrtho anticipates a preliminary Q1 2026 revenue midpoint of approximately $617.5 million, which is below market expectations due to a weaker respiratory season and slower sales in China, resulting in an 11% drop in after-hours trading.
- Flu Visits Decline: U.S. influenza-like illness visits have decreased by about 30% year-on-year, which not only impacts the company's short-term revenue but may also negatively affect future market demand, reflecting changes in overall health trends.
- Cash Flow Outlook: The company expects a first-quarter free cash flow of negative $65 million to $70 million; however, QuidelOrtho still anticipates reaching the low end of its full-year 2026 guidance, indicating some financial resilience.
- Market Environment Challenges: Proposed reimbursement changes in China and delayed orders in EMEA due to the Middle East conflict further exacerbate revenue pressures, highlighting the complex challenges and uncertainties the company faces in the global market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QDEL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QDEL
Wall Street analysts forecast QDEL stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 12.710
Low
35.00
Averages
35.00
High
35.00
Current: 12.710
Low
35.00
Averages
35.00
High
35.00
About QDEL
QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
TTP Group Sells LEX Diagnostics to QuidelOrtho
- Transaction Completed: TTP Group announced the sale of its spin-out company LEX Diagnostics to QuidelOrtho, marking TTP's exit while paving the way for global scaling of LEX Diagnostics' rapid PCR technology.
- Significant Technological Edge: LEX Diagnostics is built on ultra-fast PCR technology that delivers lab-quality results in approximately 6 to 10 minutes, providing a strong competitive advantage in the market.
- Regulatory Approval Secured: The VELO system from LEX Diagnostics has received clearance from the U.S. Food and Drug Administration (FDA) and a CLIA waiver, further enhancing its market potential and application scope.
- Optimistic Market Outlook: This transaction not only brings capital back to TTP Group but also offers QuidelOrtho an opportunity to expand its product line and market share, which is expected to drive future growth.
See More
QuidelOrtho Acquires LEX to Accelerate Growth in Molecular Diagnostics
- Acquisition Completed: QuidelOrtho has completed the acquisition of LEX Diagnostics for approximately $100 million, marking a significant milestone in its molecular diagnostics strategy and is expected to accelerate growth in the fast-paced point-of-care testing market through innovative technology integration.
- Product Innovation: The LEX VELO System has received FDA 510(k) clearance, designed to deliver highly sensitive testing results for Influenza and COVID-19 in just 6 to 10 minutes, significantly enhancing clinical decision-making speed and accuracy, thereby improving patient outcomes.
- Market Expansion Plans: QuidelOrtho expects to initiate the U.S. commercial launch of the LEX VELO System later in 2026, with global expansion anticipated following local regulatory approvals, further solidifying its leadership position in the molecular diagnostics market.
- Strategic Implications: This acquisition not only expands QuidelOrtho's molecular diagnostics portfolio but also enhances its integrated diagnostic solutions capabilities across immunoassay, clinical chemistry, and transfusion medicine, reflecting the company's long-term commitment to advanced diagnostic technologies.
See More
QuidelOrtho Acquires LEX to Accelerate Growth in Molecular Diagnostics
- Acquisition Milestone: QuidelOrtho's acquisition of LEX Diagnostics for approximately $100 million marks a strategic expansion in molecular diagnostics, expected to enhance the company's leadership in the rapidly growing point-of-care diagnostics market.
- Product Innovation: The LEX VELO System, which received FDA 510(k) clearance, can perform multiplex RT-PCR testing for Influenza and COVID-19 in 6 to 10 minutes, significantly improving clinical decision-making speed and accuracy to meet market demand for rapid testing.
- Market Launch Plans: QuidelOrtho anticipates initiating the U.S. commercial launch of the LEX VELO System later in 2026, with global expansion to follow based on local regulatory approvals, further solidifying its market share.
- Strategic Integration: This acquisition not only expands QuidelOrtho's molecular diagnostics portfolio but also enhances its integrated capabilities in immunoassay, clinical chemistry, and transfusion medicine, driving comprehensive solution delivery across the healthcare continuum.
See More
US Stocks Close Higher with Chipmakers Rallying
- Market Recovery: On Thursday, the S&P 500 rose by 0.26% and the Nasdaq 100 by 0.49%, reaching new highs, indicating a strong rebound after early losses and reflecting investor confidence in economic recovery.
- Chip Sector Boost: Taiwan Semiconductor Manufacturing Co raised its 2026 revenue forecast, highlighting strong AI demand, which propelled chipmakers' stock prices, particularly benefiting major suppliers to Nvidia and Apple, further enhancing market optimism.
- Oil Price Impact: Despite the stock market gains, crude oil prices surged over 3%, raising concerns about the Middle East situation and limiting the market's upward momentum, illustrating the potential impact of energy prices on the overall economy.
- Mixed Economic Data: Initial jobless claims fell to 207,000, exceeding expectations and indicating labor market strength, but unexpected declines in manufacturing production reflect economic uncertainty, which could influence future monetary policy.
See More
US Stocks Dip Slightly as Chipmakers Weigh on Market
- Market Performance: The S&P 500 index fell by 0.15%, the Dow Jones Industrial Average decreased by 0.06%, and the Nasdaq 100 dropped by 0.21%, indicating a slight market pullback after reaching new highs, particularly pressured by weakness in chipmakers.
- Economic Data: Initial jobless claims in the US fell by 11,000 to 207,000, indicating a stronger labor market than the expected 213,000; additionally, the Philadelphia Fed business outlook unexpectedly rose by 8.6 to a 15-month high of 26.7, reflecting potential economic recovery.
- Oil Price Fluctuations: WTI crude oil prices increased by over 1% as the US naval blockade of the Strait of Hormuz enters its fourth day, which could exacerbate global oil and fuel shortages, impacting future energy market stability.
- Earnings Season: Q1 earnings for the S&P 500 are projected to rise by 12% year-over-year, but excluding the technology sector, the earnings growth is only 3%, the lowest in two years, indicating a cautious market outlook on profit growth.
See More
US Stocks Rise Slightly, Chipmakers Rebound
- Chipmaker Rebound: Taiwan Semiconductor Manufacturing Co raised its 2026 revenue forecast, reflecting strong AI demand, which led to a rebound in chipmakers, with ON Semiconductor up over 10% and AMD up over 5%, indicating renewed market confidence in tech stocks.
- Mixed Economic Data: Initial jobless claims fell to 207,000, below the expected 213,000, suggesting a strong labor market; however, manufacturing production unexpectedly declined by 0.1%, highlighting the unevenness of economic recovery, which could influence future policy decisions.
- Oil Price Surge Impact: WTI crude oil prices rose over 2% due to escalating tensions between Iran and the US, potentially exacerbating global oil and fuel shortages, which negatively affects airline and cruise line profitability, leading to declines in related stocks.
- Earnings Season Begins: Q1 earnings for the S&P 500 are projected to rise by 12% year-over-year, but excluding the tech sector, growth is only expected at 3%, raising concerns about the profitability of non-tech stocks and potentially impacting investor confidence.
See More
TTP Group Sells LEX Diagnostics to QuidelOrtho
- Transaction Completed: TTP Group announced the sale of its spin-out company LEX Diagnostics to QuidelOrtho, marking TTP's exit while paving the way for global scaling of LEX Diagnostics' rapid PCR technology.
- Significant Technological Edge: LEX Diagnostics is built on ultra-fast PCR technology that delivers lab-quality results in approximately 6 to 10 minutes, providing a strong competitive advantage in the market.
- Regulatory Approval Secured: The VELO system from LEX Diagnostics has received clearance from the U.S. Food and Drug Administration (FDA) and a CLIA waiver, further enhancing its market potential and application scope.
- Optimistic Market Outlook: This transaction not only brings capital back to TTP Group but also offers QuidelOrtho an opportunity to expand its product line and market share, which is expected to drive future growth.
See More
QuidelOrtho Acquires LEX to Accelerate Growth in Molecular Diagnostics
- Acquisition Completed: QuidelOrtho has completed the acquisition of LEX Diagnostics for approximately $100 million, marking a significant milestone in its molecular diagnostics strategy and is expected to accelerate growth in the fast-paced point-of-care testing market through innovative technology integration.
- Product Innovation: The LEX VELO System has received FDA 510(k) clearance, designed to deliver highly sensitive testing results for Influenza and COVID-19 in just 6 to 10 minutes, significantly enhancing clinical decision-making speed and accuracy, thereby improving patient outcomes.
- Market Expansion Plans: QuidelOrtho expects to initiate the U.S. commercial launch of the LEX VELO System later in 2026, with global expansion anticipated following local regulatory approvals, further solidifying its leadership position in the molecular diagnostics market.
- Strategic Implications: This acquisition not only expands QuidelOrtho's molecular diagnostics portfolio but also enhances its integrated diagnostic solutions capabilities across immunoassay, clinical chemistry, and transfusion medicine, reflecting the company's long-term commitment to advanced diagnostic technologies.
See More
QuidelOrtho Acquires LEX to Accelerate Growth in Molecular Diagnostics
- Acquisition Milestone: QuidelOrtho's acquisition of LEX Diagnostics for approximately $100 million marks a strategic expansion in molecular diagnostics, expected to enhance the company's leadership in the rapidly growing point-of-care diagnostics market.
- Product Innovation: The LEX VELO System, which received FDA 510(k) clearance, can perform multiplex RT-PCR testing for Influenza and COVID-19 in 6 to 10 minutes, significantly improving clinical decision-making speed and accuracy to meet market demand for rapid testing.
- Market Launch Plans: QuidelOrtho anticipates initiating the U.S. commercial launch of the LEX VELO System later in 2026, with global expansion to follow based on local regulatory approvals, further solidifying its market share.
- Strategic Integration: This acquisition not only expands QuidelOrtho's molecular diagnostics portfolio but also enhances its integrated capabilities in immunoassay, clinical chemistry, and transfusion medicine, driving comprehensive solution delivery across the healthcare continuum.
See More
US Stocks Close Higher with Chipmakers Rallying
- Market Recovery: On Thursday, the S&P 500 rose by 0.26% and the Nasdaq 100 by 0.49%, reaching new highs, indicating a strong rebound after early losses and reflecting investor confidence in economic recovery.
- Chip Sector Boost: Taiwan Semiconductor Manufacturing Co raised its 2026 revenue forecast, highlighting strong AI demand, which propelled chipmakers' stock prices, particularly benefiting major suppliers to Nvidia and Apple, further enhancing market optimism.
- Oil Price Impact: Despite the stock market gains, crude oil prices surged over 3%, raising concerns about the Middle East situation and limiting the market's upward momentum, illustrating the potential impact of energy prices on the overall economy.
- Mixed Economic Data: Initial jobless claims fell to 207,000, exceeding expectations and indicating labor market strength, but unexpected declines in manufacturing production reflect economic uncertainty, which could influence future monetary policy.
See More
US Stocks Dip Slightly as Chipmakers Weigh on Market
- Market Performance: The S&P 500 index fell by 0.15%, the Dow Jones Industrial Average decreased by 0.06%, and the Nasdaq 100 dropped by 0.21%, indicating a slight market pullback after reaching new highs, particularly pressured by weakness in chipmakers.
- Economic Data: Initial jobless claims in the US fell by 11,000 to 207,000, indicating a stronger labor market than the expected 213,000; additionally, the Philadelphia Fed business outlook unexpectedly rose by 8.6 to a 15-month high of 26.7, reflecting potential economic recovery.
- Oil Price Fluctuations: WTI crude oil prices increased by over 1% as the US naval blockade of the Strait of Hormuz enters its fourth day, which could exacerbate global oil and fuel shortages, impacting future energy market stability.
- Earnings Season: Q1 earnings for the S&P 500 are projected to rise by 12% year-over-year, but excluding the technology sector, the earnings growth is only 3%, the lowest in two years, indicating a cautious market outlook on profit growth.
See More
US Stocks Rise Slightly, Chipmakers Rebound
- Chipmaker Rebound: Taiwan Semiconductor Manufacturing Co raised its 2026 revenue forecast, reflecting strong AI demand, which led to a rebound in chipmakers, with ON Semiconductor up over 10% and AMD up over 5%, indicating renewed market confidence in tech stocks.
- Mixed Economic Data: Initial jobless claims fell to 207,000, below the expected 213,000, suggesting a strong labor market; however, manufacturing production unexpectedly declined by 0.1%, highlighting the unevenness of economic recovery, which could influence future policy decisions.
- Oil Price Surge Impact: WTI crude oil prices rose over 2% due to escalating tensions between Iran and the US, potentially exacerbating global oil and fuel shortages, which negatively affects airline and cruise line profitability, leading to declines in related stocks.
- Earnings Season Begins: Q1 earnings for the S&P 500 are projected to rise by 12% year-over-year, but excluding the tech sector, growth is only expected at 3%, raising concerns about the profitability of non-tech stocks and potentially impacting investor confidence.
See More
